The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Open accessAbstract
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., & Cerami, A. (1986) · Science · doi:10.1126/science.3754653 · Cited by 1,268
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious Purpura
Girardin, E., Grau, G. E., Dayer, J.-M., Roux-Lombard, P., the J5 Study Group*, & Lambert, P.-H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190703 · Cited by 737
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., & Cerami, A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1211 · Cited by 730
Lähdevirta, J., Maury, C. P. J., Teppo, A.-M., & Repo, H. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90576-1 · Cited by 718
Landegren, U. (1984) · Journal of Immunological Methods · doi:10.1016/0022-1759(84)90477-0 · Cited by 652
Tumors secreting human TNF/cachectin induce cachexia in mice
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A., & Socher, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90028-6 · Cited by 640
RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS
Scuderi, P., Lam, K., Ryan, K., Petersen, E., Sterling, K., Finley, P., Ray, C. G., Slymen, D., & Salmon, S. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92007-6 · Cited by 458
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER
Balkwill, F., Burke, F., Talbot, D., Tavernier, J., Osborne, R., Naylor, S., Durbin, H., & Fiers, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91850-2 · Cited by 418
Evidence that tumor necrosis factor has an important role in antibacterial resistance.
Havell, E. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.9.2894 · Cited by 405
Cited by
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Tumor necrosis factor: a pleiotropic cytokine and therapuetic target
Tracey, M. D., & Cerami, P. D. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.491 · Cited by 1,063
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Self-citationThe Continuing Challenges of Leprosy
Scollard, D. M., Adams, L. B., Gillis, T. P., Krahenbuhl, J. L., Truman, R. W., & Williams, D. L. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.338-381.2006 · Cited by 928
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy
Fauci, A. S. (1993) · Science · doi:10.1126/science.8235617 · Cited by 776
Small-Molecule Inhibition of TNF-α
He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., et al. (2005) · Science · doi:10.1126/science.1116304 · Cited by 620
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Self-citationHypernociceptive role of cytokines and chemokines: Targets for analgesic drug development?
Verri, W. A., Cunha, T. M., Parada, C. A., Poole, S., Cunha, F. Q., & Ferreira, S. H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.001 · Cited by 542
Murch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993) · Gut · doi:10.1136/gut.34.12.1705 · Cited by 520
Ubiquitination in the regulation of inflammatory cell death and cancer
Cockram, P. E., Kist, M., Prakash, S., Chen, S.-H., Wertz, I. E., & Vucic, D. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00708-5 · Cited by 511
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362103 · Cited by 420
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Number VI Recurrent aphthous stomatitis
Jurge, S., Kuffer, R., Scully, C., & Porter, Sr. (2006) · Oral Diseases · doi:10.1111/j.1601-0825.2005.01143.x · Cited by 385
Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
Tseng, S., Pak, G., Washenik, K., Keltz Pomeranz, M., & Shupack, J. L. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90122-x · Cited by 367
Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A. C., Miguel, C. P., Viana, S. M., & Sarno, E. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 366
Self-citationOnen, F. (2006) · Rheumatology International · doi:10.1007/s00296-005-0074-3 · Cited by 365
Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves
Wagner, R., & Myers, R. R. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00127-3 · Cited by 363
Differential expression patterns of cytokines in complex regional pain syndrome
Üçeyler, N., Eberle, T., Rolke, R., Birklein, F., & Sommer, C. (2007) · Pain · doi:10.1016/j.pain.2007.07.031 · Cited by 350
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Muller, G. W., Chen, R., Huang, S.-Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. I. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341
Self-citationThalidomide: current and potential clinical applications
Calabrese, L., & Fleischer, A. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00408-8 · Cited by 324
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T., & Goggin, P. M. (2005) · Gut · doi:10.1136/gut.2004.047563 · Cited by 322
Zhang, M., Caragine, T., Wang, H., Cohen, P. S., Botchkina, G., Soda, K., Bianchi, M., Ulrich, P., Cerami, A., Sherry, B., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1759 · Cited by 317
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., et al. (2001) · Blood · doi:10.1182/blood.v98.4.958 · Cited by 305
Depressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Geitz, H., Handt, S., & Zwingenberger, K. (1996) · Immunopharmacology · doi:10.1016/0162-3109(95)00050-x · Cited by 291
Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma
Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2593 · Cited by 290
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., et al. (2004) · Blood · doi:10.1182/blood-2003-02-0361 · Cited by 289
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Caorsi, R., Penco, F., Grossi, A., Insalaco, A., Omenetti, A., Alessio, M., Conti, G., Marchetti, F., Picco, P., Tommasini, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210802 · Cited by 261
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Taylor, C. T., Dzus, A. L., & Colgan, S. P. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70579-7 · Cited by 188
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022123-104147 · Cited by 178
Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Self-citationClark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Byrd, T. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119436 · Cited by 90
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Choueiri, T. K., Dreicer, R., Rini, B. I., Elson, P., Garcia, J. A., Thakkar, S. G., Baz, R. C., Mekhail, T. M., Jinks, H. A., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22290 · Cited by 54
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C., Prince, H. M., & Neeson, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632399 · Cited by 52
Abouelnazar, F. A., Zhang, X., Zhang, J., Wang, M., Yu, D., Zang, X., Zhang, J., Li, Y., Xu, J., Yang, Q., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02985-9 · Cited by 24
Metadata
- Authors
- Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1991-03-01
- Volume
- 173
- Issue
- 3
- Pages
- 699-703
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2162559503
- Cited by
- 1,192
- References
- 19
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.